Excelra Named Leader in Everest PEAK Matrix
Everest Group recognized the global life sciences informatics company in its 2026 Pharmaceutical R&D IT Services assessment.
Updated on Nov. 5, 2026 in Biotech
Excelra, a global life sciences data and informatics company, was positioned as a Leader in Everest Group's Pharmaceutical R&D IT Services PEAK Matrix Assessment 2026. The assessment evaluated 34 service providers on market impact and vision and capability.
Why it matters
The ranking places Excelra among the leading providers of IT services supporting pharmaceutical research and development worldwide. For drug developers and research organizations, such assessments offer a reference point when evaluating informatics partners.
Everest Group assessed 34 service providers in the 2026 Pharmaceutical R&D IT Services PEAK Matrix, with Excelra positioned as a Leader. Excelra's flagship GOSTAR product holds 37 million bioactivity data points, though the assessment's individual category scores were not disclosed in the source material.
The players
Excelra
Excelra is a global life sciences data and informatics company headquartered in Hyderabad, India, known for its GOSTAR bioactivity database.
Everest Group
Everest Group is a global research and advisory firm that publishes PEAK Matrix assessments evaluating technology and services providers across industries.
The details
Everest Group evaluated providers through a comprehensive request-for-information process that included client references, scoring each on market impact and vision and capability. Excelra's recognition follows recent acquisitions that expanded its onshore scientific consulting talent and proximity to global clients, and its partner ecosystem spans leading cloud providers, lab informatics, and technology platforms.
Timeline
2026: Everest Group publishes the Pharmaceutical R&D IT Services PEAK Matrix Assessment naming Excelra a Leader.
Industry Landscape
Analyst PEAK Matrix assessments from Everest Group have become a common benchmark for pharmaceutical R&D IT service providers as drug developers outsource more data and informatics work. Excelra's Leader placement in the 2026 assessment places it among the providers that analysts consider most capable of meeting that demand.
For research teams choosing informatics vendors, the Leader placement offers one independent comparison point alongside client references and direct evaluations. Organizations weighing bioactivity data platforms may find the scale of GOSTAR's dataset relevant to their own sourcing decisions.
The takeaway
Analyst rankings like the PEAK Matrix provide a structured starting point for comparing pharmaceutical informatics providers, but they complement rather than replace direct evaluation of a vendor's fit with specific research workflows.
Further reading
For more on the research data tools shaping drug discovery, see Biotech.
Source note: This article includes information reported by Bizzbuzz.
